Nervous System Diseases (Neurological Disorders)

Subscribe to Selected New Research on Nervous System Diseases

3643 relevant articles (126 outcomes, 275 trials/studies) found for this Disease

Description: Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.

Also Known As:

Neurological Disorders; Neurological Disorder; Nervous System Disease; Nervous System Disorders; Neurologic Disorder; Neurologic Disorders; Disease, Nervous System; Diseases, Nervous System; Disorder, Nervous System; Disorder, Neurologic; Disorder, Neurological; Disorders, Nervous System; Disorders, Neurologic; Disorders, Neurological; Nervous System Disorder

Relationship Network

Disease Context: Research Results

Nervous System Diseases: 3643

Neurodegenerative Diseases: 8307

Demyelinating Diseases: 3391

Neurologic Manifestations: 3015

Central Nervous System Diseases: 1005

Neuromuscular Diseases: 768

Sleep Disorders: 691

Cranial Nerve Diseases: 155

Nervous System Neoplasms: 146

Neurotoxicity Syndromes: 131

Neurocutaneous Syndromes: 66

Nervous System Trauma: 44

Chronobiology Disorders: 40

Nervous System Malformations: 21

Autonomic Nervous System Diseases: 17

Autoimmune Diseases of the Nervous System: 16

Related Diseases

1.	Parkinson Disease (Parkinson's Disease)
2.	Stroke (Strokes)
3.	Epilepsy (Aura)
4.	Alzheimer Disease (Alzheimer's Disease)
5.	Pain (Aches)

Experts

1.	Farooqui, Akhlaq A: 3 articles (09/2006 - 01/2003)
2.	Horrocks, Lloyd A: 3 articles (09/2006 - 01/2003)
3.	Krupp, Johannes J: 2 articles (04/2008 - 04/2008)
4.	Fontaine, B: 2 articles (03/2007 - 03/2000)
5.	Reiss, Allison B: 2 articles (01/2007 - 09/2004)
6.	Tilley, Barbara C: 2 articles (10/2006 - 04/2005)
7.	Levine, Steven R: 2 articles (10/2006 - 04/2005)
8.	Ong, Wei-Yi: 2 articles (09/2006 - 01/2003)
9.	Granito, A: 2 articles (03/2006 - 11/2002)
10.	Corinaldesi, R: 2 articles (03/2006 - 11/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Nervous System Diseases:

1.	Botulinum Toxins (Botulinum Toxin)IBA 11/01/2002 - "Botulinum toxin has dramatically improved the treatment of a variety of neurologic disorders. " 12/01/1997 - "Botulinum toxin (BTX) has become a safe and effective therapeutic tool in the treatment of a variety of neurological disorders, especially dystonias. " 10/01/2009 - "Botulinum toxin is the most potent toxin of the peripheral cholinergic system and today it is used in the treatment of a variety of neurological disorders. " 01/01/2008 - "Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety." 01/01/2006 - "Botulinum toxin has been shown to effectively treat several types of neurological disorders. " Order ALL the reference details at left...
2.	LigandsIBA 01/01/2000 - "Immunophilin ligands as a novel treatment of neurological disorders." 01/01/2008 - "However, a number of selective 5-HT(2)R ligands currently under development, or in early clinical trials for psychiatric and/or neurological disorders, may soon be available for translational studies to explore their effectiveness in modulating drug use and dependence." 01/01/2006 - "However, a number of selective 5-HT2 R ligands currently under development, or in early clinical trials for psychiatric and/or neurological disorders, may soon be available for translational studies to explore their effectiveness in modulating drug use and dependence." 08/01/2006 - "CCR1 ligands, including CCL3, CCL5, and CCL7, are up-regulated in a number of neurological disorders in humans and animal models. " 01/01/2006 - "Some selective nicotinic ligands have recently been developed and used to explore the complexity of nAChR subtype structure and function in the expectation that they will become rational therapeutic alternatives in a number of neurodegenerative, neuropsychiatric and neurological disorders. " Order ALL the reference details at left...
3.	Proteins (Proteins, Gene)IBA 10/01/2004 - "Several groups have published the first positive results using protein transduction domains for the delivery of therapeutic proteins in relevant animal models of human neurological disorders. " 05/01/2005 - "In human cerebrospinal fluid (CSF), approximately 80% of proteins originate from serum, and removal of major proteins is necessary to study brain-derived proteins that are present at low concentrations for successful biomarker and therapeutic target discoveries for neurological disorders. " 03/01/1997 - "Based on the studies reviewed here, we conclude that grafted NT2N cells could serve as a suitable platform for the delivery of exogenous proteins into the CNS for gene therapy of human nervous system diseases." 11/01/1996 - "In this study, localization of Bax and Bcl-2 proteins was investigated in the human central nervous system using autopsy cases without any neurological disorder. " 01/01/1993 - "Probes against various synaptic proteins have recently been used to study synaptic alterations in human disease, as well as in experimental models of neurological disorders. " Order ALL the reference details at left...
4.	Tissue Plasminogen Activator (Alteplase)FDA Link 04/01/2008 - "We report a 93 year-old female subjected to intravenous thrombolysis using tissue plasminogen activator (r-tPA), according to the National Institute of Neurological Disorders protocol. " 01/01/2002 - "However, following the randomized trial of intravenous tissue-type plasminogen activator (t-PA) sponsored by the National Institutes of Neurological Disorders and Stroke (NINDS) in 1995, the first proven effective therapy for acute stroke became available. " 01/01/1999 - "BACKGROUND--With the exception of the National Institutes of Neurological Disorders and Stroke trial of recombinant tissue plasminogen activator, clinical trials in stroke have failed to show improved outcome. " 09/01/2006 - "METHODS: We used data from the IMS-1 and National Institute for Neurological Disorders and Stroke tissue plasminogen activator (tPA) stroke studies to compare outcomes among IV-IA tPA, IV-tPA, and placebo treatment stratified by the baseline CT scan appearance. " 12/01/2002 - "Results of the National Institute of Neurologic disorders and Stroke (NINDS) trial revealed a 30% greater chance of being disability free at three months if patients with acute ischemic stroke were treated with recombinant tissue plasminogen activator (rt-PA) within 3 hours of onset. " Order ALL the reference details at left...
5.	gamma-Aminobutyric Acid (GABA)IBA 06/01/1999 - "Pharmacological inhibition of GABA uptake transporters provides a mechanism for increasing GABAergic transmission, which may be useful in the treatment of various neurological disorders. " 01/01/1982 - "Trials of drugs enhancing GABA-ergic function have been made in a wide variety of neurological disorders. " 04/04/2008 - "Understanding the genetic mechanism behind such changes in alpha subunit expression will lead to a better understanding of the role that signal transduction plays in control over GABA(A)R function and brings with it the promise of providing new therapeutic tools for the prevention or cure of a variety of neurological disorders. " 02/01/2006 - "Several neurological disorders such as Alzheimer's and Parkinson's diseases have been attributed to gamma-aminobutyric acid (GABA) depletion in the brain. " 05/12/2005 - "This work is therefore expected to facilitate the design and development of new biologically active GABA analogues to treat GABA-related neurological disorders." Order ALL the reference details at left...
6.	N-Methylaspartate (NMDA)IBA 07/01/2003 - "The initial promise of the N-methyl-D-aspartate (NMDA) receptor antagonists gave hope for the therapeutic treatment of neurological disorders, which ultimately was unfulfilled. " 09/01/1988 - "These findings strongly suggest that Ca2+ entry through N-methyl-D-aspartate-activated channels is responsible for this type of neuronal death and suggest strategies that may be clinically useful in the treatment of various neurological disorders." 11/01/2008 - "N-Methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity is thought to underlie a variety of neurological disorders, and inhibition of either the NMDA receptor itself, or molecules of the intracellular cascade, may attenuate neurodegeneration in these diseases. " 02/01/2005 - "This review examines the roles of NMDA receptor subtypes in excitotoxicity and neurological disorders." 01/01/2000 - "These data challenge the notion that extracellular accumulation of endogenous QUIN may contribute to excessive NMDA-receptor activation in some neurological disorders, and the suitability of kynurenine-3-hydroxylase inhibition as an effective anti-excitotoxic strategy." Order ALL the reference details at left...
7.	EnzymesIBA 08/01/2006 - "In this review, we discuss the molecular pathologies of lysosomal diseases from the protein structural aspect, current enzyme replacement therapies, and attempts to develop enzyme replacement therapies effective for lysosomal diseases associated with neurological disorders, i.e., production of enzymes, brain-specific delivery and incorporation of lysosomal enzymes into cells." 08/01/1996 - "Therefore, the predictive value of these enzymes for the development of neurologic disorders in asphyxiated newborns is not adversely affected by the development of an immediately and effectively treated IRDS. " 04/21/2009 - "These results provide a better understanding of the role played by the enzymes that control eicosanoid synthesis and how they can be utilized as potential targets to prevent damage following either acute or potentially chronic neurological disorders." 11/01/2008 - "The advantage of using models based on real BBB cellular anatomy and physiology is that they have the power to reveal and incorporate previously undiscovered properties, such as new transporters, metabolic enzymes and modulation, to form the basis for models mimicking neurological disorders as well as normal function, and to allow physiologically-based pharmacokinetic (PBPK) extrapolation from animal models to humans." 11/15/2005 - "Mutations in enzymes involved in sphingolipid metabolism and trafficking cause a variety of neurological disorders, but details of the molecular pathophysiology remain obscure. " Order ALL the reference details at left...
8.	Intravenous Immunoglobulins (IVIG)FDA Link 04/01/2005 - "Although the use of IVIG is effective for autoimmune neurological disorders, there are no commonly accepted protocols for the use of IVIG treatment. " 04/01/1992 - "The studies cited herein highlight the potential benefits of IVIG therapy in a group of neurological disorders that are associated with aberrant immune responses. " 06/01/2009 - "The use of IVIg continues to expand despite concerns on future availability and long-term safety; alternative treatment strategies in chronic neurological disorders which require long-term, potentially indefinite therapy are warranted." 06/01/2009 - "We retrospectively reviewed all approved IVIg transfusions for neurological disorders at Careggi Hospital from 2003 to 2006. " 07/01/2008 - "IVIg in other autoimmune neurological disorders: current status and future prospects." Order ALL the reference details at left...
9.	Dopamine (Intropin)FDA LinkGeneric 04/01/2007 - "Various pharmacological studies have implicated the dopamine D(3) receptor as an interesting therapeutic target in the treatment of different neurological disorders. " 05/01/2009 - "BACKGROUND: The effects of 17beta-estradiol (E2) and xenoestrogens (XEs) on dopamine transport may have important implications for the increased incidence of neurologic disorders, especially in women during life stages characterized by frequent hormonal fluctuations. " 10/01/2008 - "The patient did not have a pre-existent neurological disorder, and had not received significant amounts of dopamine-blocking drugs. " 09/01/2008 - "The long-term consequences of exposure have become a major human health concern as research has indicated strong associations between neurotoxicants and a variety of dopamine-related neurological disorders. " 08/01/2008 - "The effects of 17beta-estradiol (E(2)) on dopamine (DA) transport could explain gender and life-stage differences in the incidence of some neurological disorders. " Order ALL the reference details at left...
10.	OxygenIBA 02/01/2002 - "While no research study has yet demonstrated convincing evidence for the efficacy of Hyperbaric Oxygen Therapy (HBOT) in patients with chronic neurological disorders (CND), anecdotal studies have been supportive of its use in improving healing of the damaged brain. " 06/01/2009 - "We evaluated the relationship between transient postoperative neurological disorders and regional cerebral oxygen saturation (rSO2) during RCP. " 11/01/1995 - "When neurological disorders were observed, HBO therapy included immediate compression to 6 atm abs for 10 to 15 mn with air followed by decompression to 2 atm abs where the patients received 100% oxygen during 1 hour. " 06/01/1993 - "These hypothetical pre- and post-HBO events may set the stage for the development of some delayed neurological disorders, including the retinopathy of prematurity and the retardation of brain development in fetuses or prematurely-born infants subjected to oxygen therapy." 01/01/2004 - "Only 6.3% had most severe neurological disorders, resulting in a GCS score of 3 - 5. Circulation parameters in the form of adapted hypotension were abnormal in only 3.4%, 21.9% of the children had a bradycardia and in 12.3% the blood oxygen saturation fell below 94%. " Order ALL the reference details at left...

Therapies and Procedures

1.	Transplantation (Transplant Recipients) 08/15/2004 - "Transplantation of genetically manipulated cells to the central nervous system holds great promise for the treatment of several severe neurological disorders. " 12/01/1995 - "After an initial postoperative exacerbation of her neurological disorder the patient developed an impressive remission of her clinical condition during the 4 year post transplantation follow up period. " 11/01/2006 - "Transplantation studies have begun in a variety of models in hopes of defining their potential use to treat a wide variety of human conditions, including diabetes and urological and neurological disorders." 11/01/2004 - "In order to verify the biological aspects of 'autogeneic' bone marrow stromal cells (BMSC) transplantation for neurological disorders, we aimed our study towards the assessment of the survival, distribution, and differentiation of autologous BMSC in the central nervous system (CNS). " 09/01/2009 - "Transplantation of neural stem cells (NSCs) has been proposed as a therapy for a range of neurological disorders. " Order ALL the reference details at left...
2.	Deep Brain Stimulation 10/15/2008 - "The use of deep brain stimulation (DBS) as an effective clinical therapy for a number of neurological disorders has been greatly hindered by the lack of understanding of the mechanisms which underlie the observed clinical improvement in patients. " 10/30/2009 - "Deep brain stimulation (DBS) is an increasingly used surgical therapy for a range of neurological disorders involving the long-term electrical stimulation of various regions of the human brain in a disorder specific manner. " 11/01/2008 - "BACKGROUND: Deep brain stimulation (DBS) has become commonplace for the treatment of medication-refractory neurological disorders. " 09/01/2007 - "The mismatch between the extensive clinical use of deep brain stimulation (DBS), which is being used to treat an increasing number of neurological disorders, and the lack of understanding of the underlying mechanisms is confounded by the difficulty of measuring the spread of electric current in the brain in vivo. " 09/01/2007 - "Chronic, high-frequency electrical stimulation of subcortical brain structures (deep brain stimulation [DBS]) is an effective clinical treatment for several medically refractory neurological disorders. " Order ALL the reference details at left...
3.	Injections 04/01/2001 - "The results suggest that the technique is safe and that BTX-A injections are effective for the treatment of sialorrhoea in patients with neurological disorders." 06/05/1993 - "The results were evaluated by means of a score taking into account the effectiveness of treatment, the duration of this effectiveness, the side-effects, if any, observed, and the course of the neurological disorder after several series of injections. " 01/01/1962 - "[On nervous system disorders caused by serum injections (with report of 7 cases).]" 11/01/2005 - "Two patients are presented with initially undetermined multisystem neurological disorders and excessive sialorrhoea, later diagnosed as mitochondrial cytopathy, who had side effects after treatment with ultrasound guided BTXA injections. " 01/01/2009 - "The aim of this study was to evaluate effects of BTX-A injections in the treatment of disabling sialorrhea in various neurological disorders. " Order ALL the reference details at left...
4.	Plasma Exchange 01/01/1999 - "We investigated 19 patients affected by chronic peripheral neurological disorders treated with therapeutic plasma exchange (TPE) to verify the efficacy of the therapeutic protocol used in these diseases. " 01/01/1981 - "Coagulation studies were performed during and after 60 continuous plasma exchanges in 15 patients with neurologic disorders. " 04/01/2008 - "Therapeutic plasma exchange (TPE) is commonly used in many neurological disorders where an immune etiology was known or suspected. " 01/01/2008 - "Neurologic disorders constitute the largest group of indications for therapeutic plasma exchange. " 02/01/2007 - "Plasma exchange is a therapeutic procedure commonly used in various neurological disorders. " Order ALL the reference details at left...
5.	Drug Therapy (Chemotherapy) 11/01/2009 - "(Gender/age data were not listed in the remaining cases.) An etiologic association of RBD with a neurologic disorder (or with pharmacotherapy of psychiatric disorders, n = 4) was present in 21-23 patients. " 11/01/2008 - "These data provide insights into NMDAR functions in the developing CNS and will contribute to designing pharmacotherapies for neurological disorders." 04/01/2008 - "Distinguishing the beneficial from the detrimental effects of PMN on neurons may aid in the development of more effective drug therapies for neurological disorders involving neuroinflammation, including painful neuropathies." 04/01/2008 - "Voltage-gated Ca(2+) channels in etiology, pathogenesis, and pharmacotherapy of neurologic disorders]" 09/01/2007 - "By providing a fine-tuning mechanism these receptors also offer attractive sites for pharmacotherapy in nervous system diseases. " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Nervous System Diseases

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 126 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>